The valsartan tablets may contain small amounts of N-nitrosodiethylamine, which is a possible human carcinogen, according to USA Today. The pharmaceutical company has not received any reports of adverse effects linked to the tablets.
Aurobindo is the latest drugmaker to recall the blood pressure drug amid heightened safety concerns over the presence of N-nitrosodiethylamine. Major Pharmaceuticals, Teva Pharmaceuticals and Mylan have also recalled valsartan products in the past year.
To view the FDA’s full recall report, click here.
More articles on pharmacy:
January’s first drug price hikes average 6.3%: 5 notes
Judge blocks Trump administration policy cutting drug payments to hospitals
Biosimilars cost up to 80% more in the US than Europe: Here’s why
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
